Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes f...
Saved in:
Main Authors: | Emily M. J. Fennell (Author), Lucas J. Aponte-Collazo (Author), Wimal Pathmasiri (Author), Blake R. Rushing (Author), Natalie K. Barker (Author), Megan C. Partridge (Author), Yuan-Yuan Li (Author), Cody A. White (Author), Yoshimi E. Greer (Author), Laura E. Herring (Author), Stanley Lipkowitz (Author), Susan C. J. Sumner (Author), Edwin J. Iwanowicz (Author), Lee M. Graves (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characterization of TR‐107, a novel chemical activator of the human mitochondrial protease ClpP
by: Emily M. J. Fennell, et al.
Published: (2022) -
Effects of ClpP protease on biofilm formation of Enterococcus faecalis
by: Ying FENG, et al.
Published: (2021) -
A Metabolomics Approach to Investigate Kukoamine B-A Potent Natural Product With Anti-diabetic Properties
by: Yuan-Yuan Li, et al.
Published: (2019) -
Mitochondrial Stress Response Gene <i>Clpp</i> Is Not Required for Granulosa Cell Function
by: Ecem Esencan, et al.
Published: (2020) -
Preclinical Model in Sepsis: Should We Abandon the CLP? [Letter]
by: Joffre J
Published: (2023)